Russia will refuse future drugs
In Russia will increase the production of biological drugs
story article
Sanctions against Russia in general and the Urals in particular
Power effects independent of foreign countries. To do this, they will increase their production in the Russian Federation, explained URA.RU following a meeting on August 3, Russian Prime Minister Mikhail Mishustin and the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova. According to analysts, there is a shortage of medicines due to disruption in the chains of their supply from abroad or the withdrawal of goods from the Russian market due to receipt.
At the beginning of the meeting, Mishustin recalled that the FMBA is engaged in the procurement of donor blood and its components. Another task is the production of drugs based on them.
Russian Prime Minister Mikhail Mishustin took another step to ensure the independence of the Russian Federation from foreign drugs
A photo: Vladimir Andreev © URA.RU
“A special challenge that we face is the supply of plasma volumes for the production of drugs. By 2024, the increase will become self-sufficient in terms of self-sufficiency in albumin and immunoglobulins,” said Skvortsova.
According to her testimony, drugs are needed to treat patients in intensive care, who are in a state of shock, with sensations of blood and fluid in places, with hematological diseases. “We are grateful for the transfer to us of the functions of identifying and detecting the bone marrow and hematopoietic stem cell registry. The FMBA has the richest experience in bone marrow donation,” the head of the FMBA specified.
Russia is fully self-sufficient in biological products by 2024, Veronika Skvortsova, head of the FMBA, announced
A photo: Vladimir Andreev © URA.RU
An important direction of the FMBA is to build the capacity of competencies in the field of biomedicine and pharmaceuticals, narrow Mishustin. “Technological independence, including in the field of medicine, scientific research, you are actively engaged in, is a priority,” the prime minister said.
For two years, scientific and technological platforms have been discovered at the FMBA that quickly create drugs of the same type, Skvortsova reports. “There are four points in the world that have reference manifestations and specific sera, different standards for assessing specific activity. These are the UK, USA, Japan and Australia. We received an offer to create a fifth site in Russia,” added the head of the FMBA.
In Russia, it is planned to build a complete chain of medicine production, taking into account the opinion of experts.
Photo: Vladimir Zhabrikov © URA.RU
New technologies of domestic medicine to ensure the biological safety of the country. This is important for Russia’s independence in the field of pharmaceuticals and medicine in general, Mishustin said.
The authorities want to build a chain of drug production in Russia – from molecules to commercial release, in order to replace foreign drugs, to increase the former chief infectious disease specialist in Moscow, virologist Nikolai Malyshev. “Many Western firms somehow protect business in the Russian Federation or experience difficulties with the delivery of medicines. The question of biosecurity of the state arose.
We must provide ourselves with the most important drugs – vaccines, bioglobulins, bioengineered drugs. Time does not endure, ”explained the expert.
The production of biological products is difficult, they are always in short supply, observed
Photo: Vladimir Zhabrikov © URA.RU
The production of biological medicines is difficult, they are always in short supply, and in conditions of limited consumption, they are considered less, so the authorities have put the products at the required level, Russian doctor Zvon Andreykov. “The FMBA structure was chosen because it meets with the management of the blood service in the country and on its borders, where it is possible to organize the production of blood products – albumin and immunoglobulin. One of the alleged drugs that the agency is releasing is albumin 4% based on plasma disease. It is always not found. Foreign analogues were received in the Russian Federation, but other detentions are 5% or 10%. Their shelf life. And Russia needs to arrange the production of its own attracting albumin. In addition, we have always had difficulty with the production of immunoglobulins, as this requires the immunization of donors,” the doctor said.
Related article
Skvortsova’s meeting with Mishustina is a step towards Russia’s independence in the field of pharmaceuticals D. I. Mendeleev, Doctor of Pharmaceutical Sciences Evgeny Abizov. “The step is very important for the development of import substitution and foreign policy pregnancy. Production in the West in Russia accounted for a large share of imported drugs, talking about self-sufficiency at such a level of foreign drugs that did not come across. I think that this meeting launches work on the safety of the life and health of Russians,” the source said.
If you want to report the news, write to us
More than a hundred thousand Russians read our news in telegram! Join and you – subscribe to the channel “URA.RU”
Power effects independent of foreign countries. To do this, they will increase their production in the Russian Federation, explained URA.RU following a meeting on August 3, Russian Prime Minister Mikhail Mishustin and the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova. According to analysts, there is a shortage of medicines due to disruption in the chains of their supply from abroad or the withdrawal of goods from the Russian market due to receipt. At the beginning of the meeting, Mishustin recalled that the FMBA is engaged in the procurement of donor blood and its components. Another task is the production of drugs based on them. “A special challenge that we face is the supply of plasma volumes for the production of drugs. By 2024, the increase will become self-sufficient in terms of self-sufficiency in albumin and immunoglobulins,” said Skvortsova. According to her testimony, drugs are needed to treat patients in intensive care, who are in a state of shock, with sensations of blood and fluid in places, with hematological diseases. “We are grateful for the transfer to us of the functions of identifying and detecting the bone marrow and hematopoietic stem cell registry. The FMBA has the richest experience in bone marrow donation,” the head of the FMBA specified. An important direction of the FMBA is to build the capacity of competencies in the field of biomedicine and pharmaceuticals, narrow Mishustin. “Technological independence, including in the field of medicine, scientific research, you are actively engaged in, is a priority,” the prime minister said. For two years, scientific and technological platforms have been discovered at the FMBA that quickly create drugs of the same type, Skvortsova reports. “There are four points in the world that have reference manifestations and specific sera, different standards for assessing specific activity. These are the UK, USA, Japan and Australia. We received an offer to create a fifth site in Russia,” added the head of the FMBA. New necessary technologies of domestic medicine to ensure the biological safety of the country. This is important for Russia’s independence in the field of pharmaceuticals and medicine in general, Mishustin said. The authorities want to build a chain of drug production in Russia – from molecules to commercial release, in order to replace foreign drugs, to increase the former chief infectious disease specialist in Moscow, virologist Nikolai Malyshev. “Many Western firms somehow protect business in the Russian Federation or experience difficulties with the delivery of medicines. The question of biosecurity of the state arose. We must provide ourselves with the most important drugs – vaccines, bioglobulins, bioengineered drugs. Time does not endure, ”explained the expert. The production of biological medicines is difficult, they are always in short supply, and in conditions of limited consumption, they are considered less, so the authorities have put the products at the required level, Russian doctor Zvon Andreykov. “The FMBA structure was chosen because it meets with the management of the blood service in the country and on its borders, where it is possible to organize the production of blood products – albumin and immunoglobulin. One of the alleged drugs that the agency is releasing is albumin 4% based on plasma disease. It is always not found. Foreign analogues were received in the Russian Federation, but other detentions are 5% or 10%. Their shelf life. And Russia needs to arrange the production of its own attracting albumin. In addition, we have always had difficulty with the production of immunoglobulins, as this requires the immunization of donors,” the doctor said. Skvortsova’s meeting with Mishustina is a step towards Russia’s independence in the field of pharmaceuticals D. I. Mendeleev, Doctor of Pharmaceutical Sciences Evgeny Abizov. “The step is very important for the development of import substitution and foreign policy pregnancy. Production in the West in Russia accounted for a large share of imported drugs, talking about self-sufficiency at such a level of foreign drugs that did not come across. I think that this meeting launches work on the safety of life and health of Russians,” the source said.